A Randomized, Placebo-controlled, Parallel Group, Patient-blinded, Multi-center, Phase I Pilot Study to Assess Tolerability and Safety of Two Doses of AFFITOPE PD03A Formulated With Adjuvant to Patients With Early Parkinson's Disease

Trial Profile

A Randomized, Placebo-controlled, Parallel Group, Patient-blinded, Multi-center, Phase I Pilot Study to Assess Tolerability and Safety of Two Doses of AFFITOPE PD03A Formulated With Adjuvant to Patients With Early Parkinson's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Affitope PD03 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man
  • Sponsors AFFiRiS
  • Most Recent Events

    • 07 Jun 2017 Top Line results from this study published in an AFFiRiS Media Release.
    • 07 Jun 2017 According to an AFFiRiS media release, data from this trial were presented at the 21st International Congress of Parkinsons Disease and Movement Disorders.
    • 28 Oct 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top